Europe approves Ponvory (ponesimod) for multiple sclerosis
The European Commission has approved once daily oral Ponvory (ponesimod) for the treatment of relapsing multiple sclerosis in adult patients.
List view / Grid view
News
EU secures up to 1.8 billion additional doses of Comirnaty® COVID-19 vaccine
Pfizer and BioNTech have agreed to supply Europe with 900 million additional doses of Comirnaty® with the option to request 900 million more in future.
EMA’s human medicines committee (CHMP) meeting highlights, May 2021
In its latest meeting the CHMP recommended eight medications for approval, 17 medicines for indication extension and concluded reviews of two COVID-19 treatments.
CDMO sector are the big winner of the pandemic, state experts
In a presentation, experts revealed that contract services gained significantly through pandemic contracts but cautioned that capacity shortages could continue.
Stelara® “a compelling option” for the treatment of Crohn’s disease
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC).
Are COVID-19 vaccines effective for immunocompromised patients with haematological malignancies?
A new study will evaluate COVID-19 vaccines in patients with haematological malignancies who have received cellular therapy.
Imbruvica®-based regimens induce lasting remissions in leukaemia trials
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
FDA issues draft guidance on trials for medical devices to improve glycaemic control
The guidance outlines recommendations for early trials testing the feasibility of medical devices intended to improve glycaemic control for type 2 diabetes.
Ziltivekimab shows promise in atherosclerosis trial
Ziltivekimab was found to reduce inflammatory biomarkers of atherosclerosis by up to 93 percent in patients with chronic kidney disease and high cardiovascular risk.
UK patients with rare blood disorders receive new treatment option
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
Dexpramipexole could be a promising treatment for eosinophilic asthma
Oral doses of dexpramipexole lowered eosinophil counts by up to 80 percent and showed signs of improving lung function in a Phase II eosinophilic asthma trial.
Nanomedicine to dominate nanobots market in coming years
Novel research shows that nanomedicine and biomedical applications of nanobots will lead the global market between 2021 and 2029.
Neutralising antibodies, a proxy for COVID-19 vaccine efficacy, shows study
Researchers have shown that the early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time.
Evinacumab shows promise in severe hypertriglyceridemia trial
The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis.
mRNA COVID-19 vaccination is immunogenic in the immunocompromised
Research suggests patients who receive COVID-19 vaccines prior to a transplant and subsequent immunosuppression may be protected from the disease.
